Michael Makris/LinkedIn
Mar 2, 2026, 13:42
Michael Makris: How Early Can Hemlibra Be Started?
Michael Makris, Emeritus Professor of Haemostasis and Thrombosis at the University of Sheffield, shared a post on LinkedIn about a recent article by Eman Hassan et al, published in RPTH Journal:
”How early can you start Hemlibra (emicizumab)?
A paper in the RPTH Journal describes its effective use when started at 26 hours of age, in a baby with hemophilia born 10 weeks premature (at 30 weeks of gestation).”
Title: Emicizumab Prophylaxis in a Preterm Infant with Severe Haemophilia A: A Case Report on the Feasibility of Early Use
Authors: Eman Hassan, Charles Percy, Amna Ahmed, Gillian Lowe, Will Lester, Neil V. Morgan, Jayashree Motwani
Read the Full Article on RPTH Journal․
Other articles featuring Michael Makris on Hemostasis Today.
-
Jul 16, 2026, 20:25Ilham Benzidia: Leaving ISTH 2026 With New Ideas and New Collaborations
-
Jul 16, 2026, 20:23Eman Hassan: A Fantastic Platelets and Megakaryocytes Session at ISTH 2026
-
Jul 16, 2026, 20:22Sankara Nelson Noah II: Investigating the Temporal Dynamics of Platelet – Leukocyte Interactions in Early Sepsis
-
Jul 16, 2026, 20:20Joseph Pierre Aboumsallem: Paris Certainly Delivered This Week, and Not Just Because of the Heat
-
Jul 16, 2026, 19:53Louise St. Germain Bannon: The End of Congress, the Beginning of New Collaborations
-
Jul 16, 2026, 19:18Steve Humphreys: Learning From the Leading Experts at ISTH 2026
-
Jul 16, 2026, 19:02Kellie Machlus: Where Science Meets Friendship at ISTH 2026
-
Jul 16, 2026, 18:51Aaron Paul Kithcart: When Clinical Research Comes Together at ISTH 2026
-
Jul 16, 2026, 18:40Sara Buonomo: Predicting Relapse in Immune-Mediated TTP at ISTH 2026